The measurement of blood pressure in primary care is a simple screening test to identify individuals at high risk of cardiovascular disease, including stroke. Hypertension is one of the most important preventable causes of premature morbidity and mortality 1 and a recent analysis of combined epidemiological data indicates that the relation between blood pressure and cardiovascular disease is much steeper than previously thought; 2 in other words, the potential benefits of intervention are higher. Allied to these impressive population data is a clinical-trials evidence base larger than any other in clinical medicine, pointing to the effectiveness of antihypertensive therapy in reducing cardiovascular risk. 3 This evidence has provided the substrate for numerous guidelines on detection and treatment. The Chief Medical Officer for England has identified hypertension as one of his five priority areas, and the treatment of hypertension is a key target in National Service Frameworks for the prevention of coronary heart disease and stroke.
Although there are claims for drug-specific benefits, the effectiveness of antihypertensive therapy is most powerfully determined by the reduction in blood pressure achieved on treatment-i.e. by the quality of blood pressure control. 2, 3 Yet, according to the Health Survey for England, the proportion of hypertensive patients who in 1998 achieved a blood pressure goal of <140/90 mmHg was only some 10%. 4 The annual impact of this shortfall in treatment has been calculated by He and MacGregor 5 as about 62 000 unnecessary deaths and 125 000 cardiovascular events that could have been prevented.
The study by Professor Walley and his colleagues reported in this issue (p. 525) 6 is the largest retrospective survey of hypertension treatment yet conducted in the UK, involving over 20 000 patients treated in primary care. The findings are disturbing. After a minimum 4 years of followup, only 14% of patients on treatment had achieved the recommended blood pressure target. We might console ourselves with the hope that, since the patients began treatment in the mid-1990s, things will surely be much better today-but they are not. Importantly, the study provides insight into a key reason why blood pressure is so poorly controlled in UK patients-namely, the high rate of monotherapy. Over 65% of people with moderate to severe hypertension were treated with a single blood-pressurelowering drug, whereas clinical trials have consistently demonstrated that the typical patient requires more than one drug to achieve good-quality control. 7 The earlier Health Survey for England 4 made a very similar observation: only one-third of patients treated for hypertension received more than one drug and less than 10% received more than two drugs. The 'real world' management of hypertension in the UK seems hard to defend when we consider the potential effectiveness of treatment.
What can be done to improve matters? If more than one drug is necessary to control blood pressure, then guidelines should offer specific advice on which drug combinations are likely to be complementary. In response, the British Hypertension Society (BHS) launched its ABCD algorithm, to provide more didactic advice on the sequencing of drugs. 8 This algorithm is based on simple principles. The first is that younger people (<55 years) generally respond better to drugs that block the renin system-these include 'A' drugs (angiotensin converting-enzyme inhibitors or angiotensin receptor blockers) and 'B' drugs (b-blockers). In contrast, older people (>55 years) and black people respond better initially to 'C' drugs (calcium channel blockers) or 'D' drugs (diuretics). Second, for the majority who will require more than one drug, the logical strategy is to combine A or B with C or D; it is not logical at step 2 to combine A with B or C with D. The third step would involve triple therapy with either A+C+D or B+C+D. Where possible and when there is no cost disadvantage, at step 2 fixed-dose combinations would be appropriate to reduce the number of medications. This algorithm approach replicates the process adopted in clinical trials, which invariably achieve better blood-pressure control than realworld clinical practice. Whilst providing a template for rational prescribing it is not restrictive, in that it offers choice within a structured framework. Finally, the patient can be offered an individual treatment plan that sets out the objectives and the strategy required to reduce his or her blood pressure.
What is clear is that improvement on the very poor figures for blood-pressure control in the UK will not come from a new drug but rather from a sharper focus on implementation and process. To some in the medical
Vocational rehabilitation
An all-too common effect of sickness or disability is exclusion from the world of work, and thus from ordinary society. To counter it, an approach now favoured by disability rights groups, 1 the Government 2 and the health professions 3,4 goes under the name of vocational rehabilitation, the aim being to facilitate working for those who are willing and potentially able. The strategies can be described as top-down and bottom-up.
Top-down approaches to vocational rehabilitation relate to government policy, and were reviewed earlier this year by the Organization for Economic Co-operation and Development (OECD). 5 The report outlines the strategies used by member states to meet two potentially conflicting goals-to enable people with disabilities to participate optimally in society (and particularly to engage in gainful employment) and at the same time to ensure that those unable to work have income security. So what can governments do? The report calls for recognition that the status of disability is independent of an individual's ability to work; that those with disabilities have obligations to society as well as the reverse; that, to achieve employment, many need individual work/benefit packages; and that employers are crucial to this process.
An important driving force is the need to maximize the workforce, now shrinking in relation to the population of old or sick or disabled people requiring support. So governments are offering financial incentives to facilitate employment and trying to remove financial disincentives. The legislative approaches differ from country to country. In Austria, Denmark, Spain, Sweden and Switzerland a request for benefits is automatically treated as a request for vocational rehabilitation; in Germany, Norway and Poland, the degree of compulsion is slightly less; whilst in Australia, Canada, France, Italy, Korea, Mexico, Portugal, the UK and the USA vocational rehabilitation is entirely voluntary.
For health professionals, the vital message of the report concerns early intervention-the most effective measure against long-term ill health and consequent dependence on benefits. In this respect the strategy usually pursued in the UK, whereby the patient's possible return to work is considered only after completion of medical care, has come in for strong criticism. 3 By contrast, Germany requires vocational rehabilitation to be part of the process before, during and after medical rehabilitation.
Increasing numbers in the UK are receiving incapacity benefits (now nearly 2.7 million) and efforts to halt or reverse the trend include strategies for minimizing work-
